If not, please take a few moments to fill out the form below. It’s free, and ensures that you receive regular alerts to the latest clinical news and other content.

Keep me logged in Forgot your password?

Please wait...

Please wait...

Prostate Cancer

PSA Screening Reduces Prostate Cancer Mortality, European Study Shows

May 24, 2012

The European Randomized Study of Screening for Prostate Cancer (ERSPC), which included 186,160 men, suggests that PSA screening can lower prostate cancer mortality rates.
 

New Assay Identifies Men Who May Be at Lower Risk for PCa Recurrence After Surgery

May 23, 2012

A recently approved diagnostic assay may improve clinicians' ability to predict a prostate cancer patient's risk of clinical recurrence after radical prostatectomy (RP), a company announced at the American Urological Association 2012 annual meeting.
 

Oral Drug Prolongs Survival in Men with Late-Stage PCa

May 23, 2012

Enzalutamide, an investigational oral medication formerly known as MDV3100, prolongs survival by nearly five months in men with late-stage prostate cancer previously treated with docetaxel, according to data presented at the American Urological Association 2012 annual meeting.
 

Intermittent ADT May Offer Survival Edge in Advanced Prostate Cancer

May 22, 2012

Intermittent androgen deprivation (IAD) therapy is associated with improved all-cause and prostate cancer (PCa)-specific mortality among elderly patients with advanced PCa, according to data presented at the American Urological Association 2012 annual meeting.
 

Durable Oncologic Outcomes Reported for RARP

May 22, 2012

Robotic-assisted radical prostatectomy (RARP) is associated with long-term biochemical relapse-free survival, according to a study presented at the American Urological Association 2012 annual meeting.
 

Urologists Condemn Task Force's Anti-PSA Testing Stance

May 22, 2012

The U.S. Preventive Services Task Force (USPSTF) on May 21 released its final recommendations on PSA-based screening for prostate cancer (PCa), which advises against the practice and gives it a grade D rating, meaning the task force believes there is "moderate or high certainty that the service has no net benefit or that the harms outweigh the benefit."
 

UTUC Tumor Location Affects Oncologic Outcomes

May 21, 2012

Tumor location independently predicts cancer-specific survival (CSS) and recurrence-free survival (RFS) in patients with upper tract urothelial carcinoma (UTUC), researchers reported at the American Urological Association 2012 annual meeting.
 

Post-RP Survival Unaffected by Early Biochemical Recurrence

May 21, 2012

Early biochemical recurrence after radical prostatectomy (RP) has no effect on survival among patients with low-risk prostate cancer (PCa), according to a study presented at the American Urological Association 2012 annual meeting.
 

HIFU Salvage Following EBRT Offers Good PCa Control

May 21, 2012

High-intensity focused ultrasound (HIFU) provides shows promise as a salvage treatment option men with recurrent prostate cancer (PCa) following external beam radiotherapy (EBRT), data presented at the American Urological Association annual meeting suggest.
 

PCa-Specific Survival Can Be Good Even with Positive Nodes

May 21, 2012

Prostate cancer (PCa) patients with lymph node positive disease found at radical prostatectomy (RP) can experience durable cancer-specific and metastases-free survival, researchers reported at the American Urological Association 2012 annual meeting.
 

Cure Possible Despite Positive Lymph Nodes

May 21, 2012

Long-term PSA relapse-free survival after radical prostatectomy (RP) and pelvic lymph node dissection (PLND) is possible in a subset of patients with low volume nodal metastases, a researcher reported at the American Urological Association 2012 annual meeting.
 

Inappropriate Post-RP Medication Use Found

May 20, 2012

A significant proportion of men take 5-alpha reductase inhibitors (5-ARIs) and alpha blockers following radical prostatectomy (RP) even though these medications have no proven role post-RP, according to study findings presented at the American Urological Association 2012 annual meeting.
 

Bladder Cancer More Likely with Radiotherapy

May 20, 2012

Radiation therapy for prostate cancer (PCa) is associated with a greater likelihood of bladder cancer development compared with radical prostatectomy (RP), Japanese researchers reported at the American Urological Association 2012 annual meeting.
 

Findings Support Use of Salvage RALP

May 20, 2012

Salvage robotic-assisted laparoscopic prostatectomy (RALP) for recurrent prostate cancer (PCa) appears to be safe and offers outcomes favorable to those of open salvage radical prostatectomy, investigators reported at the American Urological Association 2012 annual meeting.
 

Smokers Have Worse PCa Outcomes After EBRT

May 20, 2012

Cigarette smoking is associated with an increased risk of prostate cancer (PCa) progression and genitourinary (GU) toxicities following treatment with external beam radiation therapy (EBRT), researchers reported at the American Urological Association 2012 annual meeting.
 

PCa Patient Survival Better with RP

May 20, 2012

Radical prostatectomy (RP) is associated with better overall and disease-specific survival compared with external beam radiation therapy (EBRT) for localized prostate cancer (PCa), according to findings presented at the American Urological Association 2012 annual meeting.
 

Marriage Has a Positive Effect on Prostate Cancer Outcomes

May 20, 2012

Being married is a plus when it comes to prostate cancer (PCa) outcomes, according to the findings of two studies presented at the American Urological Association 2012 annual meeting.
 

Circumcision May Lower Prostate Cancer Risk

May 17, 2012

Circumcision may help protect against prostate cancer, according to researchers in Seattle.
 

Optimal Sequencing of the New Prostate Cancer Drugs: An Interview with E. David Crawford, MD

May 15, 2012

Several new drugs have become available for treating advanced prostate cancer in the past year and a half. E. David Crawford, MD, head of urologic oncology at University of Colorado (UC) Hospital and an investigator at the UC Cancer Center, both in Aurora, and UC colleague Thomas W. Flaig, MD, recently published a review of these agents. Dr. Crawford talks to Renal & Urology News about the possible ways in which these drugs might be used.
 

Prostate Cancer Outcome Not Tied to Complementary Medicine

May 07, 2012

Although widely used, complementary and alternative medicine (CAM) does not impact patient satisfaction with treatment or patient-reported outcomes after treatment for localized prostate cancer.
 
Kidney Week 2011

Our exclusive coverage of Kidney Week 2011 in Philadelphia includes interviews, videos and noteworthy clinical reports.

Sections: Anemia | Transplantation
Secondary Hyperparathyroidism | General News
More: Videos

On The Forefront


On The Forefront

A 55-year-old Caucasian woman initially presented to one of Cleveland Clinic's regional outpatient urology clinics with gross hematuria and an obstructing right ureteral stone.

Latest CME Article

Renal & Urology News includes a CME article in every print issue, which will also be available online.

View the latest installment:

May CME

Managing Bone Disease in 
Kidney Transplant Recipients

Expert Q&A

Optimal Sequencing of the New Prostate Cancer Drugs: An Interview with E. David Crawford, MD

E. David Crawford, MD


Several new drugs have become available for treating advanced prostate cancer in the past year and a half. Dr. Crawford talks to Renal & Urology News about the possible ways in which these drugs might be used.
 Subscribe to the RSS for this page  [view all our RSS feeds here]

 

© 2012 Haymarket Media, Inc.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions